Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2373012 | 1.00 | CFTR (0.70) | CFTRNOTUM | |
| SCHEMBL22775073 | 0.95 | CFTR (0.64) | CFTRNOTUM | |
| SCHEMBL14783370 | 0.89 | CFTR (0.57) | CFTRNOTUM | |
| SCHEMBL24241489 | 0.85 | CFTR (0.54) | CFTRNOTUM | |
| SCHEMBL30396668 | 0.85 | CFTR (0.54) | CFTRNOTUM | |
| SCHEMBL23616410 | 0.85 | CFTR (0.61) | CFTR | |
| SCHEMBL18652620 | 0.84 | CFTR (0.58) | CFTR | |
| SCHEMBL4767342 | 0.84 | CFTR (0.58) | CFTR | |
| SCHEMBL23671475 | 0.82 | CFTR (0.59) | CFTR | |
| SCHEMBL14783593 | 0.82 | CFTR (0.62) | CFTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118974058-A | Preparation method and crystalline form of (6A, 12A) -17-amino-12-methyl-6, 15-bis (trifluoromethyl) -13, 19-dioxa-3,4,18-triazatricyclo [12.3.1.12,5] nonadeca-1 (18), 2,4,14,16-pentaen-6-ol | 弗特克斯药品有限公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-116670140-A | Macrocyclic compounds containing 1,3, 4-oxadiazole rings as modulators of cystic fibrosis transmembrane conductance regulator | 弗特克斯药品有限公司 | 2023-08-29 | — | — | CN | disclosed |
| CN-116171154-A | Modulators of cystic fibrosis transmembrane conductance regulator | 弗特克斯药品有限公司 | 2023-05-26 | — | — | CN | disclosed |
| EP-3980121-A1 | PYRIDINE AND PYRAZINE DERIVATIVE FOR THE TREATMENT OF CF, COPD, AND BRONCHIECTASIS | Novartis AG (CH) | 2022-04-13 | — | — | EP | disclosed |